OBJECTIVE: To explore the effects of simvastatin on tumor growth, blood coagulation in mice with colorectal cancer based on microRNA (miR)-181/ nuclear factor (NF)-κB pathway. METHODS: The colorectal cancer mice model was established by subcutaneous injection of human colorectal cancer cell line SW480, and 30 model mice were randomly divided into the control group, simvastatin low-dose group and simvastatin high-dose group. The simvastatin low-dose group and simvastatin high-dose group were intraperitoneally injected with 50 mg/ kg and 100 mg/ kg simvastatin, qd. On the 28th day, tumor growth, angiogenesis, coagulation indicators were analyzed. The expression levels of miR-181, IκBα and NF-κB mRNA and protein in tumor tissues were detected by quantitative reverse transcription polymerase chain reaction and western blotting. RESULTS: Compared with the control group, the tumor volume, mass, CyclinD1 protein, Ki67 protein, Bcl-2 protein, microvessel density, vascular endothelial growth factor (VEGF) levels, whole blood viscosity, IκBα and NF-κB mRNA and protein expression levels of the simvastatin low-dose group and simvastatin high-dose group decreased significantly, while Bax protein and miR-181 levels increased, plasma prothrombin time ( PT), activated partial thromboplastin time ( APTT) and miR-181 were prolonged significantly, with statistically significant differences ( P < 0. 05 ). The tumor volume, mass and microvascular density in simvastatin high-dose group were significantly lower than those in simvastatin low-dose group [(171. 74±19. 33) mm3 vs. (226. 52±26. 38) mm3, (0. 21±0. 03) g vs. (0. 28±0. 04)g, (9. 77±1. 85)% vs. (16. 39±2. 11)%], CyclinD1, Ki67 and Bcl-2 protein levels, VEGF levels, whole blood viscosity, expression levels of IκBα and NF-κB mRNA and protein were significantly lower than those in simvastatin low-dose group; the levels of Bax protein and miR-181 were significantly higher than those of simvastatin low-dose group, PT and APTT were significantly longer than those of simvastatin low-dose group, the differences were statistically significant (P<0. 05). CONCLUSIONS: Simvastatin may inhibit tumor growth and angiogenesis in colorectal cancer model mice by regulating the miR-181/ NF-κB pathway, and alleviate blood hypercoagulability. [ABSTRACT FROM AUTHOR]